Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

A single-arm, interventional study combining Immunotherapy and propranolol with/without chemotherapy and propranolol 1. Pancreatic Cancer Durvalumab will be administered once every 4 weeks, in combination with gemcitabine + nab-paclitaxel (day 1/8/15) and continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients. 2. HCC Durvalumab will be administered once every 4 weeks in combination with continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression i

Trial Details

NCT ID

NCT05451043

Phase

PHASE2

Sponsor

AHS Cancer Control Alberta

Status

RECRUITING

Cancer Type

Cholangiocarcinoma (Bile Duct) Liver Cancer

Interventions

Durvalumab
Gemcitabine
Nab paclitaxel
Tremelimumab
Propranolol
Cisplatin

Locations (sample)

Edmonton, Alberta, Canada|53.55014,-113.46871

Key Eligibility Criteria

Patients must be 18 years of age or older.
Body Weight \>30kg
Life expectancy of at least 12 weeks
Patients must have a diagnosis of histologically documented advanced pancreatic adenocarcinoma, hepatocellular carcinoma, or BTC not amenable to cu…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cholangiocarcinoma (Bile Duct) Liver Cancer Trials on Trialify →